Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.62 |
| ▸ | REN | P00797 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PEPD | P12955 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MVD | P53602 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4177769 | 1.00 | ACE (0.62) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL11995957 | 1.00 | ACE (0.62) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL4180188 | 0.98 | ACE (0.60) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL9171568 | 0.94 | ACE (0.56) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL18897070 | 0.94 | ACE (0.56) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL13041423 | 0.86 | ACE (0.55) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL7052372 | 0.85 | ACE (0.64) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL10537366 | 0.85 | ACE (0.64) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL7052375 | 0.85 | ACE (0.64) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL13272263 | 0.85 | ACE (0.45) | ACERENLMNAHSD17B10CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AVANTOR PERFORMANCE MATERIALS, LLC (US) | 2025-11-06 | — | — | US | claimed |
| EP-4319795-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | Avantor Performance Materials, LLC (US) | 2024-02-14 | — | — | EP | claimed |
| CN-117355321-A | Performance enhancing excipients and methods for reducing viscosity and improving stability of biological agents | 安万托特性材料股份有限公司 | 2024-01-05 | — | — | CN | claimed |
| WO-2022217021-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AVANTOR PERFORMANCE MATERIALS, LLC (US) | 2022-10-13 | — | — | WO | claimed |
| US-8846699-B2 | Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof | HANMI PHARM. CO., LTD. (KR) | 2014-09-30 | — | — | US | claimed |
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | claimed |
| US-20090186853-A1 | COMPOSITIONS COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU RUEY J | 2009-07-23 | — | — | US | claimed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | claimed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | claimed |
| EP-1865953-A4 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU RUEY J (US) | 2008-04-30 | — | — | EP | claimed |
| EP-1865953-A2 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | Yu, Ruey J., Dr. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | claimed |
| WO-2006101940-A2 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU, RUEY, J. (US) | 2006-09-28 | — | — | WO | claimed |
| US-20060211754-A1 | Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof | YU RUEY J | 2006-09-21 | — | — | US | claimed |
| US-20050171194-A1 | Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions | YU RUEY J (US) | 2005-08-04 | — | — | US | claimed |
| WO-2005055947-A2 | ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS | YU RUEY J (US) | 2005-06-23 | — | — | WO | claimed |
| EP-0416282-B1 | Microbiologically produced N-Acyl-L-proline-acylase, process for its production and its use | DEGUSSA (DE) | 1994-09-14 | — | — | EP | claimed |
| EP-0416282-A1 | Microbiologically produced N-Acyl-L-proline-acylase, process for its production and its use | Degussa Aktiengesellschaft (DE) | 1991-03-13 | — | — | EP | claimed |
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AVANTOR PERFORMANCE MATERIALS, LLC (US) | 2025-11-06 | — | — | US | disclosed |
| CN-86101850-A | N, the manufacture method and the purposes of N '-dialkyl group guanidine radicals dipeptides | — | 1987-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AADAT, KYNU, PNISR | ACE 1279/4885REN 1983/4885LMNA 2142/4885 |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | ABL1, JAK1, BTK | ACE 190/4885REN 136/4885LMNA 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.